All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Powering insights from Cortellis. Link to Cortellis page on Clarivate website.
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing the state of COVID-19 testing
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, January 17, 2021
Home » Topics » Asia-Pacific » Australia

Australia
%{topic} RSS Feed RSS

Australia and coronavirus

Australian researchers develop COVID-19 test that detects variability in patients’ immune systems

Last updated: Dec. 18, 2020
By Tamra Sami
No Comments
PERTH, Australia – Researchers at the QIMR Berghofer Medical Research Institute in Queensland have developed a way of testing whether COVID-19 patients’ immune systems are gearing up to fight the virus that causes the disease.
Read More

Chimeric closes AU$35M IPO to progress CAR T made from scorpion toxin

Last updated: Dec. 29, 2020
By Tamra Sami
No Comments
PERTH, Australia – Chimeric Therapeutics Ltd. closed an IPO on the Australian Securities Exchange (ASX:CHM), raising AU$35 million (US$26.5 million) to fund its CAR T trial in glioblastoma.
Read More

Chimeric closes AU$35M IPO to progress CAR T made from scorpion toxin

Last updated: Dec. 14, 2020
By Tamra Sami
No Comments
PERTH, Australia – Chimeric Therapeutics Ltd. closed an IPO on the Australian Securities Exchange (ASX:CHM), raising AU$35 million (US$26.5 million) to fund its CAR T trial in glioblastoma.
Read More
Product image

Control Bionics raises AU$15M in IPO to fund global expansion

Last updated: Dec. 11, 2020
By Tamra Sami
No Comments
PERTH, Australia – Med-tech company Control Bionics began trading on the Australian Securities Exchange (ASX:CBL) Dec. 7 in an IPO that saw the company raise AU$15 million (US$11.25 million). Melbourne-headquartered Control Bionics develops assistive technologies (AT) that allow people with severe disabilities to communicate and control electronic devices using electromyography (EMG).
Read More
Australian flag marking country on globe

Implantable device manufacturers must include patient implant cards, leaflets in Australia

Last updated: Dec. 4, 2020
By Tamra Sami
No Comments
PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) is requiring manufacturers of permanently implantable devices to provide patient implant cards and consumer device leaflets with their devices, beginning Dec. 1. New implantable devices will need to comply by Dec. 1, 2020, and existing implantable devices will have until Dec. 1, 2021, to comply.
Read More
Australia map, flag

Australia unveils new framework for personalized medical devices, 3D-printed devices

Last updated: Dec. 2, 2020
By Tamra Sami
No Comments
PERTH, Australia – Australia’s Therapeutic Good Administration (TGA) has unveiled its final regulatory requirements for personalized medical devices, including 3D-printed devices, that go into effect on Feb. 25, 2021. Under the previous framework, custom-made medical devices were exempt from the requirement to be included in the Australian Register of Therapeutic Goods (ARTG).
Read More
Hematologic DNA blood test

Australia’s Telix to acquire Swiss Therapharm for hematology assets in AU$33M deal

Last updated: Dec. 1, 2020
By Tamra Sami
No Comments
PERTH, Australia – Melbourne-based Telix Pharmaceuticals Ltd. is acquiring Scintec Diagnostics GmbH subsidiary Therapharm GmbH in a deal worth AU$33 million (US$24.24 million) plus royalties. Zug, Switzerland-based Therapharm has developed a portfolio of radiolabeled diagnostic and therapeutic products, and the deal brings Telix a new targeting asset in hematology, Telix CEO Chris Behrenbruch told analysts during a Dec. 1 conference call.
Read More
Drugs-in-space-CubeLab-pic-11-19

University of Adelaide begins space odyssey into pharmaceutical stability

Last updated: Nov. 24, 2020
By Tamra Sami
No Comments
PERTH, Australia – As the idea of going to Mars starts to look less far-fetched, scientists are beginning to ask practical questions about how space affects the stability of drugs.
Read More
Respiratory infection

Mesoblast licenses remestemcel-L to Novartis in deal worth up to $1.3B

Last updated: Nov. 24, 2020
By Tamra Sami
No Comments
PERTH, Australia – Mesoblast Ltd. inked an exclusive global licensing deal with Novartis AG for the development, manufacture and commercialization of Mesoblast’s mesenchymal stromal cell product remestemcel-L, with an initial focus on the acute respiratory distress syndrome, including that associated with COVID-19, just six weeks after the FDA issued a complete response letter for the therapy as a treatment for steroid-refractory acute graft-versus-host disease.
Read More

Australia’s Imugene shows positive overall survival in ongoing phase II gastric cancer trial

Last updated: Nov. 25, 2020
By Tamra Sami
No Comments
PERTH, Australia – Sydney-based Imugene Ltd.’s stock shot up 15% on news that an interim analysis of phase II data in its B-cell peptide vaccine, HER-Vaxx, in advanced gastric cancer showed positive survival data, and the data monitoring committee said it could lower the number of patients required for study completion.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 20 21 Next

Popular Stories

  • British flag

    Accuracy, utility of COVID-19 lateral flow tests questioned in the U.K.

    BioWorld MedTech
    LONDON – A huge row has broken out in the U.K. about the accuracy and utility of COVID-19 lateral flow tests (LFT) in screening asymptomatic people, as a pilot...
  • Total artificial heart being manufactured

    Carmat's artificial heart receives CE mark

    BioWorld MedTech
    Carmat SA said its total artificial heart received the CE mark, and the company plans to ramp up production to enable the launch of the device in the second...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan. 15.
  • Israeli flag

    Israel continues to shine as hub of med-tech innovation

    BioWorld MedTech
    In recent years, Israel has proven to be a hot spot for med-tech innovation. The country boasts more than 1,500 companies in the health care and life sciences...
  • Doctor examining child in wheelchair

    Sarepta DMD phase II hangs in ‘balance’ as disparity in North Star leads astray

    BioWorld
    Sarepta Therapeutics Inc.’s miss on a key phase II ambulatory endpoint in its Duchenne muscular dystrophy (DMD) trial may have been caused by a dramatic disparity...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing